The objective of these studies was to evaluate the potential toxicity of Triapine (a ribonucleotide reductase inhibitor with potential antitumor activity) in dogs and rats. Various doses (1-20 mg/kg) of Triapine were administered intravenously (IV), once daily for 1, 3, or 5 consecutive days, to Beagle dogs or Albino Sprague-Dawley rats. Control animals were treated with vehicle, with an amount equivalent to a dose of 20 mg/kg of Triapine. Data collected included body weights, clinical signs, clinical pathology (serum chemistry and hematology), and gross and microscopic pathology. In dogs, the no-observed-adverse-effect level (NOAEL) of Triapine, when administered once daily for 5 consecutive days, was 1 mg/kg. For 5 daily doses at 3 mg/kg, or a single dose at 10 mg/kg, Triapine induced only limited toxicity (emesis and diarrhea, causing inappetence and body weight loss). The intensities/frequencies of the clinical signs were greater when Triapine was administered over 15 minutes than 120 minutes. Ondansetron (an antiemetic agent due to its H 2 antagonistic properties) delayed, but did not eliminate, emesis induced by 10 mg/kg of Triapine. In rats, the NOAEL of Triapine, when administered once daily for 5 consecutive days, was not determined. However, when administered once daily for 3 consecutive days, 1 mg/kg was considered the NOAEL. Five to 20 mg/kg of Triapine (and its vehicle) induced a wide-range of toxicity. Toxicity related to the vehicle (as re ected by the similar or greater intensity/frequency of these effects in vehicle-treated rats than Triapine-treated rats) were reduced activity, discolored urine, discolored tails, and the accompanying gross and histopathological ndings. Triapine-related effects were mortality; reductions in total protein and albumin levels; reductions in red blood cell, white blood cell, and platelet counts; reductions in body and thymic weights; increases in the liver and lung weights (and the corresponding microscopic ndings of these organs); and microscopic ndings of the adrenal cortex, testes, bone marrow, and kidney. These effects generally increased in a dose-related manner between 5-15 mg/kg, and leveled off at 15 and 20 mg/kg. Essentially all effects induced Received 30 September 1999; accepted 3 December 1999. Address correspondence to King C. Lee, Vion Pharmaceuticals, Inc., Four Science Park, New Haven, CT, 06511, USA. E-mail: klee@vionpharm.com by Triapine and /or vehicle had returned, or were returning, to normal during a 30-day recovery period. In conclusion, the NOAEL of Triapine was 1 mg/kg, when administered daily for 5 consecutive days, in dogs. Five daily doses at 3 mg/kg or a single dose at 10 mg/kg Triapine-induced emesis and diarrhea. The toxicity was greater when Triapine was administered over 15 minutes than over 120 minutes. Ondansetron had limited ef cacy in attenuating the emetic effects of the high dose (10 mg/kg) of Triapine. In rats, the NOAEL of Triapine was 1 mg/kg when administered once daily for 3 consecutive days. At 5-20 mg/kg, Triapine induced a broad spectrum of toxicological effects, which is consistent with its ribonucleotide reductase inhibitory properties. Essentially all effects induced by Triapine and /or vehicle were reversible within 30 days.
Triapine is a ribonucleotide reductase (RR) inhibitor. RR is an enzyme that is responsible for the reduction of ribonucleotides to deoxyribonucleotides in the biosynthesis of DNA. This reduction process is a rate-limiting step due to the extremely low levels of deoxyribonucleotides in mammalian cells . Good indirect correlation between tumor growth rate and speci c activity of RR has been established (Elford et al. 1970) . Accordingly, an inhibitor of ribonucleotide reductase is expected to be effective in treating cancer, and a number of RR inhibitors are currently under clinical development for the treatment of tumors.
Mammalian RR is a dimeric structure. Each subunit consists of a nucleotide binding site (M1) and a metal binding site (M2). Triapine is a M2-affecting RR inhibitor. The M2 subunit contains non-heme iron and a tyrosine free radical, which are required for the enzymatic reduction of ribonucleotides (Cory, Cory, and Chiba 1989) . Inhibitors of the M2 subunit act by destroying the free radical. In the case of hydroxyure a (HU), which is the only clinically approved RR inhibitor acting at the iron/free radical site, the inhibition is reversible due to the ease in regenerating the tyrosine free radical by mammalian cells (Wright et al. 1990 ). The M1-affecting RR inhibitors are nucleoside analogs, several of which are currently under clinical development. One analog has recently been approved for the treatment of pancreatic cancer (i.e., gemcitabine).
Triapine belongs to the class of M2-affecting RR inhibitors that are derivatives of a -heterocyclic carboxaldehyde thiosemicarbazone (HCT) (Cory et al. 1994) . The HCTs are the most potent RR inhibitors, being 65 to 5000 times more potent than HUs (Liu, Lin, and Sartorelli 1992; Liu et al. 1995) . Although the initial lead compound in the HCT series, 5-hydroxy-pyridine -2-carboxaldehyde thiosemicarbazone (5-HP), exhibited a broad spectrum of antitumor activity in transplanted animal models, a Phase I clinical study showed that it was inactive in patients with solid tumors (DeConti et al. 1972; Moore, Booth, and Sartorelli 1971) . The ineffectiveness in cancer patients is presumably due to the rapid metabolism (via formation and subsequent elimination of the O-glucuronide conjugate) of 5-HP, resulting in a short biological half-life (t 1/ 2 ) of 2.5 to 10 minutes in patients (Krakoff et al. 1974) . The 3-amino-containing HCT derivatives, 3-AP and 3-amino-4-methylpyridine-2-carboxaldehyd e thiosemicarbazone (3-AMP), were designed to avoid this metabolic fate. They have been shown to possess potent antitumor activity against the L1210 leukemia and M109 lung carcinoma in vitro and in vivo, with 3-AP being more potent than 3-AMP (Liu, Lin, and Sartorelli 1992; Liu et al. 1996) . The improved antitumor activity of these 3-amino-containing HCT derivatives is attributed to the absence of O-glucuronide conjugate formation and increased potency against RR, according to animal studies. It has further been shown that 3-AP has antitumor activity against L1210 leukemia (which con rms results from previous studies described above), HU-resistant L1210 leukemia, and human A2780 tumor (Cory et al. 1994; unpublished observation) in vitro and in animals. Due to the promising preclinical results, 3-AP is currently under clinical development to evaluate its safety and antitumor ef cacy in patients.
The objective of these studies was to perform toxicological evaluation of Triapine in dogs and rats.
MATERIALS AND METHODS

Materials
Triapine (Vion Pharmaceuticals, Inc.) is a 10-ml injectable formulation, containing 5 mg/ml of 3-AP. The formulation also contains 6 mg/ml of citric acid (anhydrous, USP, a chelating agent), 1 mg/ml of L-Ascorbic acid (USP, an antioxidant), 0.3 ml of ethyl alcohol (anhydrous, USP, a solvent), and 0.7 ml of polyethylene glycol 300 (USP, a solvent). Vehicle, used in the control animals, had the same composition as Triapine, except for the absence of 3-AP. The amount of vehicle administered to the control animals was equivalent to a dose of 20 mg/kg. Ondansetron HCl (Lot# 62P1045) was obtained from Sigma Chemical Company (St. Louis, MO).
Animals
Adult Albino Sprague-Dawley Crl:CD rats (approximately 170-350 g, Charles River Laboratories, Raleigh, NC, Kingston, NY) and young adult laboratory bred Beagle dogs (approximately 9-15 kg and 8-14 months old, Marshall Farms, North Rose, NY) were used. The animals were individually housed in stainless steel cages. The rooms were well ventilated (> 10 air changes per hour, with 100% non-recirculated fresh air), with controlled temperature (22 § 3 ± C for rats and at 20 § 2 ± C for dogs) and relative humidity (30-70%). The room had a 12-hour light/dark photocycle. Tap water and food (Certi ed Rodent Chow for rats and Certi ed Canine Diet for dogs, both PMI Feeds, Inc., Richmond, IN) were available ad libitum. All animals were acclimated to laboratory conditions for approximately 7 to 14 days prior to study initiation. Handling and care of the animals were according to USDA Animal Welfare Act (9 CFR Parts 1, 2 and 3); and The Guidelines for Care and Use of Laboratory Animals (National Academy Press, Washington, DC, 1996) .
Experimental Design
Three studies in dogs and three in rats were conducted ( Table 1 ). The rst canine study evaluated the possible doserelated acute toxicity of Triapine at 1 and 3 mg/kg, administered intravenously (IV) over 15 minutes. The second canine study evaluated the possible dose-related subchronic toxicity of Triapine at 1 and 3 mg/kg, administered by an IV infusion over 15 minutes once daily for 5 consecutive days. This study also evaluated the potential differences in the toxicity of Triapine at 3 mg/kg, when administered over 15 versus 120 minutes. The third canine study evaluated the possible antagonistic effects of ondansetron (an antiemetic agent due to its H 2 antagonistic properties) on Triapine-induced emesis.
The rst rodent toxicological study evaluated the acute toxicity of Triapine at 10 and 20 mg/kg, administered by an IV bolus injection. The second rodent toxicological study evaluated the subchronic toxicity of Triapine at 1-10 mg/kg, administered by an IV bolus injection once daily for 3 consecutive days. The last rodent toxicological study evaluated the subchronic toxicity of Triapine at 5-20 mg/kg, administered by an IV bolus injection once daily for 5 consecutive days. This study also evaluated the degree of recovery, within 30 days, of the toxicological effects induced by Triapine at 10 mg/kg. = once daily for 3 consecutive days.
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Necropsy performed 1 day after the last dose.
2
Necropsy performed 30 days after the last dose.
3
Day 1 being the rst day of dosing. Histopathology was performed in a variety of tissues in all animals in the third rodent studies.
87 mean corpuscular hemoglobin, mean corpuscular volume, and mean corpuscular hemoglobin concentration), white blood cells (total and differential cell counts [neutrophils, lymphocytes, monocytes, eosinophils, basophils, and large unstained cells]), and platelets (counts).
Clinical Signs and Body Weight
Daily observations for abnormal clinical signs were performed, at least twice daily, before and after Triapine or vehicle treatment. Body weights were determined before, during, and after Triapine or vehicle treatment, and at necropsy.
Necropsy and Histopathology
A complete gross necropsy was performed in all animals that were found dead or euthanized (for humane reasons because of poor health conditions), and in all animals at the end of most studies (Table 1 ). Animals were euthanized by exsanguination, while under deep anesthesia induced with sodium pentobarbital. Appropriate tissues and organs were collected and examined during gross necropsy. The weights of the following organs were determined: adrenals, epididymides, kidneys, lungs, pituitary, testes, thyroid with parathyroids, brain, heart, liver, ovaries, spleen, and thymus.
The following tissues were preserved: cardiovascular (aorta 
Statistical Analyses
Differences between treatment groups were analyzed using one-way analysis of variance (ANOVA), followed by the Dunnett's test for pairwise comparison. Differences were considered signi cant if p < .05. Quantitative results are expressed as mean § standard of deviation (SD).
RESULTS
First Canine Study: Dose-Ranging Acute Toxicity
Following a single IV administration of Triapine at 1 or 3 mg/kg, no mortality or any effects on body weight or clinical pathology parameters were observed (based on results obtained 6 days after dosing comparing to predose values). No abnormal clinical signs were observed in dogs treated with a single dose of 1 mg/kg. However, a single dose at 3 mg/kg induced emesis at 10 and 30 minutes after dosing in two of three dogs.
Second Canine Study: Dose-and Duration-Ranging Subchronic Toxicity
No treatment-related effects on body weights, clinical signs, clinical pathology, or gross necropsy were observed in dogs treated with 1 mg/kg of Triapine, administered over 15 minutes daily for 5 consecutive days. At a dose of 3 mg/kg, administered over either 15 or 120 minutes, emesis and diarrhea occurred. The incidences (as re ected in occurrences and frequency) of the emetic effects were higher in dogs infused with Triapine over 15 minutes than over 120 minutes (Table 2) . Similar degrees of inappetence were observed in these two groups. Body weight loss was observed in all dogs treated with 3 mg/kg of Triapine, and was greater in dogs with 15-minute Triapine infusion (approximately 10% reduction, predose versus day 6 values) than in dogs with 120-minute Triapine infusion (approximately 7% reduction). No treatment-related effects on clinical pathology or necropsy were observed in dogs treated with 3 mg/kg of Triapine.
Third Canine Study: Antiemetic Evaluation
Triapine-induced (IV, 10 mg/kg over 15 minutes) emesis with similar frequency in all four dogs pretreated with ondansetron, and all four dogs not pretreated with ondansetron. However, the onset of emesis after Triapine treatment was delayed by ondansetron. Speci cally, the onsets of emesis in the four dogs with ondansetron pretreatment were 10, 10, 15, and 90 minutes. In the four dogs without ondansetron pretreatment, they were 1, 1, 5, and 10 minutes.
First Rodent Study: Dose-Ranging Acute Toxicity
A single IV bolus injection of Triapine at 10 and 20 mg/kg induced dose-related clinical signs in rats. The clinical signs and their incidence (provided in parenthesis) were: red urine (two of four rats at 10 mg/kg and all four rats at 20 mg/kg); prostration (one of four rats at 10 mg/kg, and all four rats at 20 mg/kg); salivation (one of four rats at 10 mg/kg and all four rats at 20 mg/kg); and stained/wet pelvis (one of four rats at 10 mg/kg and all four rats at 20 mg/kg). No mortality occurred at 10 mg/kg, but two of four rats (both males) treated with 20 mg/kg died on day 3. Body weight was not signi cantly affected (when compared to historic data of normal weight gain in rats of similar age) at 10 or 20 mg/kg. The hematological values, on day 6, were not affected by a single dose of Triapine at 10 or 20 mg/kg. At necropsy, transudative uid within the thoracic cavity was observed in the two male rats (treated with 20 mg/kg) that died during the study. No gross ndings were observed in the surviving rats in both dose groups. 
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Second Rodent Study: Dose-Ranging Subchronic Toxicity Triapine at 1 mg/kg, administered as an IV bolus once daily for 3 consecutive days, did not induce any clinical signs. At 3 and 10 mg/kg, a dose-related increased incidence in clinical signs was observed. The clinical signs and incidence (given in parenthesis) were: pallor (3 of 10 rats at 3 mg/kg and all 10 rats at 10 mg/kg); wet /stained pelvis (1 of 10 rats at 3 mg/kg and 6 of 10 rats at 10 mg/kg); red urine (none at 3 mg/kg and 10 of 10 rats at 10 mg/kg); and salivation (none at 3 mg/kg and 9 of 10 rats at 10 mg/kg). No mortality occurred at 1 and 3 mg/kg, but 1 of 10 rats treated with 10 mg/kg died on day 2. Body weight was not signi cantly affected (when compared to normal weight gain in rats of similar age) at 1, 3, or 10 mg/kg. No overt hematological effects were observed at all three doses. A slight decrease in mean hemoglobin and hematocrit values may have occurred in rats treated with 3 and 10 mg/kg, when compared to rats treated with 1 mg/kg. However, without any concurrent control values, a treatment-related effect could not be ascertained. Gross necropsy evaluation did not reveal any abnormality in the surviving rats, but transudative uid within the thoracic cavity was observed in the rat that was found dead on day 2.
Third Rodent Study: Dose-Ranging Subchronic Toxicity and Recovery Evaluations
An IV bolus injection of Triapine, administered at a dose of 5 or 10 mg/kg once daily for 5 consecutive days, did not induce death. However, 5 rats treated with 15 mg/kg and 13 rats treated with 20 mg/kg, died. Two rats treated with vehicle (plus six more in the recovery group) also died. Clinical signs of discolored tails, discolored urine, and reduced activity were observed in all groups. The incidence of these clinical signs was the greatest in rats treated with vehicle, 15 and 20 mg/kg, which received the largest volume of the vehicle. In the recovery rats treated with vehicle or 10 mg/kg Triapine, only clinical signs at the injection site area (discolored and/or ulcerated tail) were still observed on day 36. Between days 1 and 5, the average body weights were reduced in all groups (Table 3 ). The body weight reductions in the Triapine groups were dose-related. In recovery rats, the weight gain in the 10 mg/kg group was equal to or greater than controls. Table 4 summarizes the results of the clinical pathology parameters that were affected by vehicle or Triapine treatment. Inspite of the decreased number of survivors in some groups which limited the interpretation of the results, some treatment-related effects were evident. Among all serum chemistry parameters, only albumin and total protein were affected. Their values were reduced in all groups, but the decrease was greater in the 15 and 20 mg/kg groups than other Triapine groups. For the hematology parameters, reductions in red blood cell counts and related indexes (hemoglobin and hematocrit) occurred in Triapine groups and, to a lesser extent, the vehicle groups, when compared to historic data from rats of similar age. These hematological values were signi cantly lower in rats treated with 5-20 mg/kg of Triapine when compared to vehicle-treated rats. Decreases in white blood cell counts (attributable to decreased neutrophils and lymphocytes) were observed in all Triapine groups. A slight decrease in the platelet counts occurred in all Triapine groups. The reductions in red blood cell, white blood cell, and platelet counts seemed to follow a similar pattern: the reductions were, or tended to be, dose-related between 5-15 mg/kg, and they leveled off between 15 and 20 mg/kg. In the vehicle and 10 mg/kg recovery rats, red blood cell counts and related indices (hemoglobin and hematocrit), total protein, and albumin and platelet values had returned to normal, and white blood cell counts had started to increase in the 10 mg/kg recovery rats.
At necropsy, the predominant nding in early death rats (occurred on days 1-5) treated with vehicle and Triapine was watery, transudative yellow, red or clear uid within the thoracic cavity, which was not observed in rats that were euthanized on day 6 or day 36. The predominant nding in all early death and scheduled euthanized rats treated with vehicle or Triapine was tail/injection site or skin discolorations and/or lesions corresponding generally to congestion, hemorrhage, and subepithelial or supraepithelial deposits of leaked blood/serum/hemoglobin crystals which were still present in recovery animals at day 36. Table 3 summarizes the results of the organ-to-bod y weight ratios from those organs that were affected by vehicle or Triapine treatment. Dose-related reductions in thymic-to-body weight ratios were observed in all Triapine groups, which tended to correlate with the incidence of small thymuses found in gross necropsy. Dose-related increases in lung-to-body weight ratios were observed at 10 or 15 mg/kg, and tended to leveled off between 15 and 20 mg/kg. The liver-to-body ratios tended to follow the same pattern, although only the values at 15 mg/kg were signi cantly higher than those from vehicle treatment. The adrenal-to-body weight ratio was signi cantly reduced at 15 and 20 mg/kg of Triapine. By day 36, these organ weights in the 10 mg/kg-treated rats had normalized and were comparable to vehicle recovery rats. The mean spleen and heart weights in some Triapine groups were different from the vehicle group. However, when normalized to the body weight, these were similar in all groups.
Histopathological ndings involved the tail (necrosis/ brinoid necrosis, edema, hemorrhage, serum/blood/hemoglobin crystals, and congestion) and lungs ( brinous alveolitis) in both Triapine and vehicle rats. In all Triapine-treated rats, thymic lymphoid cortical depletion and macrophage in ltration, adrenal cortical degeneration/vacuolar degeneration, and hypocellular bone marrow with degeneration were observed. In rats treated with 10, 15, and 20 mg/kg, spermatidic giant cells and degeneration of seminiferous tubules in the testes (with increased numbers of degenerate spermatogenic cells in the lumens of epididymal tubules) were observed. At 15 and 20 mg/kg, basophilic tubules in the kidney were seen. In the vehicle and 10 mg/kg recovery rats, no evidence of necrosis in lymphoid organs, bone marrow, or intestinal basal epithelium was observed. However, minimal degeneration/vacuolar degeneration persisted in the adrenal glands of some animals; one male still had
TABLE 3
Treatment-related effects observed during necropsy in Triapine-and vehicle-treated rats Triapine was administered intravenously, as a single dose daily, for 5 consecutive days beginning on day 1.
2
There were 8/sex/rats in each of the seven treatment groups at the onset. Results (expressed as mean § SD) presented were derived from surviving rats that were euthanized on day 6 or day 36, and those that died on day 6 or day 36. Triapine was administered intravenously, as a single dose daily, for 5 consecutive days beginning on day 1.
3
The % values were directly correlated, whereas the absolute values were indirectly correlated, with the dose of Triapine.
2
There were 8/sex/rats in each of the seven treatment groups at the onset. Results (expressed as mean § SD) presented were derived from surviving rats that survived and were euthanized on day 6 or day 36.
92 seminiferous tubular degeneration with increased numbers of degenerate spermatogenic cells in the epididymis, and one female had erythroid hyperplasia in the bone marrow with evidence of increased erythrogenesis in the spleen.
DISCUSSION
The objective of these studies was to evaluate the potential toxicity of Triapine in dogs and rats. Three studies in dogs, and 3 studies in rats, on Triapine were performed. In rats, IV bolus injection of Triapine or vehicle, administered once daily for 5 consecutive days at doses of 5-20 mg/kg, produced a widerange of toxicity. The clinical signs of reduced activity, discolored urine, discolored tails, and the accompanying gross and histopathological ndings, were related to the vehicle. Although partially induced by vehicle, the following effects were related to Triapine: mortality; reductions in total protein and albumin levels; reductions in red blood cell, white blood cell, and platelet counts; reductions in body and thymic weights; increases in the liver and lung weights (and the corresponding microscopic ndings of these organs); and microscopic ndings of the adrenal cortex, testes, bone marrow, and kidney. The hematological effects may be due to a combination of frequent blood sampling during the study and an inhibition of DNA biosynthesis by Triapine. The reductions in body and thymic weights may be due to a combination of Triapine-induced DNA biosynthesis and treatment-related stress. The increase in lung weight may be related to uid accumulation in this organ. The intensity of most of these effects were dose-related between 5-15 mg/kg, and leveled off at 15 and 20 mg/kg. The NOAEL of Triapine, when administered daily for 5 consecutive days in rats, was not determined because some effects on body and organ weights and hematology (although mild) were observed at the lowest dose tested (5 mg/kg). Essentially all effects induced by Triapine and/or vehicle were reversible. When administered once daily for 3 consecutive days, 1 mg/kg was found to be the NOAEL in rats.
The broad spectrum of toxicological effects of Triapine is consistent with its RR inhibitory properties. RR is an enzyme that is responsible for the reduction of ribonucleotides to deoxyribonucleotides in the biosynthesis of DNA. At high doses (as those used in these studies), the biosynthesis of DNA of most cells in the body are inhibited by Triapine, resulting in a broad spectrum of toxicity. Furthermore, Triapine (like all cytotoxic antitumor agents) may have a narrow therapeutic margin, according to the present rodent toxicology studies. Therefore, the current Phase I human clinical trial in patients with tumors employs a conservative dose-escalation scheme. Speci cally, small increments of dose-escalation are used and no patients are tested at a higher dose level until safety data are obtained from at least three patients from the previous dose levels.
In dogs, no treatment-related effects were observed at 1 mg/kg of Triapine, when administered over 15 minutes once daily for 5 consecutive days. Triapine at 3 mg/kg, administeredover either 15 or 120 minutes for 1 or 5 consecutive days, induced mild toxicological effects (i.e., emesis and diarrhea).
The canine studies also showed that the incidences of emesis, diarrhea, and body weight loss were directly related to the rate of administration. These effects were greater when Triapine was administered over 15 minutes than over 120 minutes. The direct relationship between the incidence of the gastrointestinal effects, and the rate of administration, may be related to the higher plasma 3-AP levels associated with the faster rate of administration (Lee et al. 1999 ). Additionally, the canine studies also show that Ondansetron has limited ef cacy in attenuating the emetic effects of high dose (10 mg/kg) of Triapine. Due to these observations, the current Phase I trials of Triapine involve a 120-minute infusion of Triapine in all patients, and antiemetic pretreatment is given only to some patients.
